Segmentation by type classifies the COVID‑19 In‑Vitro Diagnostics market into PCR kits, rapid antigen kits, serology (antibody) kits, automated testing platforms, and home‑use kits. PCR kits, which include reagents, extraction buffers, and control materials, remain the largest type segment, reflecting the dominance of molecular testing and contributing proportionally to the 45 % application share. Rapid antigen kits, designed for lateral‑flow or fluorescence readouts, align with the 30 % antigen application share and are valued for turnaround times under 30 minutes. Serology kits, encompassing ELISA, chemiluminescence, and lateral‑flow formats, support the antibody application segment and are critical for epidemiological assessments. Automated platforms integrate sample preparation, amplification, and detection in high‑throughput instruments, enabling laboratories to scale capacity; they draw revenue from both molecular and serology applications. Home‑use kits, approved for self‑collection and on‑site analysis, are a growing niche that bridges point‑of‑care and consumer markets, expanding the overall market size through increased test volumes and accessibility.